Testing for the presence of HER2 (ERBB2) gene amplification for the prediction of the tumor response to anticancer treatment by anti-ERBB2 monoclonal antibody has fundamentally transformed the oncology of gastric cancer [18]. This evidence concerns the gene ERBB2 and gastric cancer.